Lucid Diagnostics Issues Stock for PAVmed Compensation
Company Announcements

Lucid Diagnostics Issues Stock for PAVmed Compensation

Lucid Diagnostics (LUCD) has released an update to notify the public and investors about the unregistered sales of equity securities.

Lucid Diagnostics Inc. and its parent company PAVmed Inc. have agreements wherein PAVmed manages certain activities for Lucid, provides resources, and covers payroll and benefit expenses. PAVmed can opt to be compensated in Lucid’s common stock according to the agreement terms. On January 26, 2024, PAVmed chose to receive $4,675,256 in fees and reimbursements through the issuance of 3,331,771 Lucid common stock shares. This amount is equal to what PAVmed will distribute to its stockholders by February 15, 2024.

For further insights into LUCD stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
Carrie WilliamsLUCD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
TheFlyLucid Diagnostics granted patent underlying its EsoGuard Esophageal DNA Ttest
TheFlyCastle Biosciences price target raised to $40 from $35 at BTIG
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App